Bizarre Patents
Mouse device with a built-in printer
A mouse device for use as an input device of a computer is provided that includes a housing in which recording paper is loadable, and a printer unit provided within the housing for printing on the recording paper print information received from the computer.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7279169 | Mucosal DTPa vaccines Mucosal DTPa vaccines, especially intranasal vaccines, comprising (a) a diphtheria antigen, a tetanus antigen and an acellular pertussis antigen, and (b) a detoxified mutant of cholera toxin (CT) or E. coli heat labile toxin (LT). Component (b) acts as a muco... | 10/09/2007 |
| 7223412 | Staphylococcal enterotoxin SEC-SER, expression vector and host cell, production method thereof, and manufacturing method of vaccine The present invention relates to a method of producing recombinant modified Staphylococcal toxin having improved stability, comprising the steps of preparing a modified toxin in which a specific amino acid sequence is substituted and a vector for expressing the modi... | 05/29/2007 |
| 7169392 | serogroup B glycoconjugates and methods of producing the same The present invention pertains generally to novel Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (Men... | 01/30/2007 |
| 7070781 | Nontoxic mucosal adjuvant A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating t... | 07/04/2006 |
| 6962703 | Clostridial toxin derivatives able to modify peripheral sensory afferent functions The invention relates to an agent specific for peripheral sensory afferents. The agent may inhibit the transmission of signals between a primary sensory afferent and a projection neutron by controlling the release of at least one neurotransmitter or neuromodulator f... | 11/08/2005 |
| 6855321 | Polyepitope carrier protein The invention relates to polyepitope carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. The... | 02/15/2005 |
| 6835818 | Mutants of Streptococcal toxin C and methods of use This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-l... | 12/28/2004 |
| 6723321 | Autoinducer synthase modulating compounds and uses thereof Provided are compositions and methods useful for modulating the activity of autoinducer synthase catalysts. A method for identifing modulators of the autoinducer synthesis reaction is also provided. Such modulators are useful for controlling bacterial growth and can... | 04/20/2004 |
| 6448226 | Bacillus thuringiensis strains and their insecticidal proteins The present invention relates to transformed plants and plant cells comprising DNA molecules encoding Bacillus thuringiensis proteins with insecticidal activity. The invention relates more particularly to transformed plants and plant cells comprising DNA ... | 09/10/2002 |
| 6337075 | Methods for treating diabetes The invention encompasses a method for treating hyperinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into the pancreas, thereby reducing insulin secretion from a B cell, and a method for treating hypoinsulin... | 01/08/2002 |
| 6203794 | Modification of clostridial toxins for use as transport proteins A chemical conjugate for treating a nerve cell related disorder is provided. The conjugate includes an active or inactive Clostridial toxin having specificity for a target nerve cell. The toxin is conjugated to a drug or other bioactive molecule without a... | 03/20/2001 |
| 6150156 | Bacillus thuringiensis isolates active against sucking insects The subject invention concerns novel Bacillus thuringiensis strains containing parasporal proteins with pesticidal properties against whitefly, aphid, jassid, and possibly other sucking insects of agronomic importance, and peptide sequences to these prote... | 11/21/2000 |
| 6110470 | Pasteurella multocida toxin derivatives A vaccine for immunizing animals against diseases caused by microorganisms producing an osteolytic toxin comprising an immunologically effective amount of a recombinant, immunogenic, detoxified Pasteurella multocida toxin or toxin analog, the vaccine bein... | 08/29/2000 |
| 6051239 | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents Compositions and methods of oral delivery of an antigen or therapeutic agent to the general circulation using a modified botulinum toxin which is capable of translocating from the gut to the general circulation but which is altered to be nontoxic are prov... | 04/18/2000 |
| 6033673 | Double mutant enterotoxin for use as an adjuvant The present invention is directed towards a novel composition which is a genetically distinct mutant of E. coli heat-labile enterotoxin (LT). Specifically, the mutant LT designated LT(R192G/L211A) is modified by two amino acid substitutions, i.e., the arg... | 03/07/2000 |
| 5989545 | Clostridial toxin derivatives able to modify peripheral sensory afferent functions The invention relates to an agent specific for peripheral sensory afferents. The agent may inhibit the transmission of signals between a primary sensory afferent and a projection neuron by controlling the release of at least one neurotransmitter or neurom... | 11/23/1999 |
| 5932209 | Bacillus thuringiensis δ-endotoxin An improved Bacillus thuringiensis (B.t.) delta-endotoxin is created by the modification of the gene encoding the toxin. The toxicity of a B.t. toxin was improved by replacing the native protoxin segment with an alternate protoxin segment by constructing ... | 08/03/1999 |
| 5925546 | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine Immunological active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating a microorganism transformed with a hybrid plasmid including ... | 07/20/1999 |
| 5889172 | DNA sequences for immunologically active peptides of pertussis toxin Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating a microorganism transformed with a hybrid plasmid includin... | 03/30/1999 |
| 5871750 | Leukotoxin vaccine compositions and uses thereof New proteins and subunit antigens from P. haemolytica for use in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are disclosed. The subunit antigens include immunogenic amino acid sequences of P. ha... | 02/16/1999 |
| 5837265 | Chemically-modified clostridiatoxin with improved properties The invention consists of modified Clostridium neurotoxin compounds, pharmaceutical compositions containing such compounds and methods for preparing such compounds. In particular, the compounds of the invention are purified Clostridium botulinum and Clost... | 11/17/1998 |
| 5821238 | Recombinant pseudomonas exotoxin with increased activity This invention relates to the production and use of recombinant Pseudomonas-derived toxins modified to increase their toxicity and potency in therapy. More particularly, the invention relates to certain deletions in domain II of the amino acid sequence of... | 10/13/1998 |
| 5792458 | Mutant diphtheria toxin conjugates A potent and specific immunotoxin is prepared by coupling an inactivated diphtheria toxin to a binding moiety such as a monoclonal antibody or transferrin. The immunotoxins are specific for human tumors and leukemias and are indistinguishable in cell toxi... | 08/11/1998 |
| 5770203 | Modified cholera toxin based on mutagenized subunit A The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-... | 06/23/1998 |
| 5728383 | Treatment of tumors of the central nervous system with immunotoxins Potent and specific immunotoxins are prepared by conjugation of moieties binding to receptors on the surface of tumor cells to a mutant diphtheria toxin having A-chain translocation activity, but lacking membrane-binding activity. The immunotoxins are use... | 03/17/1998 |
| 5601827 | Diphtheria toxin vaccines A DNA encoding an immunologically cross-reactive form of diphtheria toxin Fragment A, wherein the codons corresponding to Val-147 and Glu-148 of naturally-occurring diphtheria toxin are deleted from the DNA.... | 02/11/1997 |
| 5360897 | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having at least one reducing group and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The in... | 11/01/1994 |
| 5352447 | Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy A potent and specific immunotoxin is prepared by coupling a binding-site inactivated diphtheria toxin (CRM 107) to a new binding moiety consisting of transferrin or a monoclonal antibody against the human transferrin receptor. These immunotoxins are tumor... | 10/04/1994 |
| 5306492 | Oligosaccharide conjugate vaccines The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular p... | 04/26/1994 |
| 5244657 | Genetic detoxification of pertussis toxin A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this in... | 09/14/1993 |
| 5223255 | Bordetella pertussis variants A Bordetella pertussis variant which produces a pertussis toxin mutant protein partially devoid of subunits. When the variants of the present invention are cultured, a pertussis toxin mutant protein partially devoid of subunits, particularly at least subu... | 06/29/1993 |
| 5153312 | Oligosaccharide conjugate vaccines The present invention relates to an improved method for producing oligosaccharide conjugate vaccines. In an additional aspect of the invention, oligosaccharide vaccines are produced which elicit a monospecific and homogeneous immune response to capsular p... | 10/06/1992 |
| 5097020 | Immunogenic conjugates An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having at least one reducing group and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The in... | 03/17/1992 |
| 5085862 | Genetic detoxification of pertussis toxin A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this in... | 02/04/1992 |
| 4902506 | Immunogenic conjugates An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having at least one reducing group and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The in... | 02/20/1990 |
| 4898815 | Novel synthetic peptide, process for its preparation and medicaments containing it The invention provides a synthetic peptide which reproduces at least 5 of the 11 amino acids common to the γ chain of sub-unit A of cholera toxin and the γ chain of LT toxin of Escherichia coli. It is preferably constituted by a pentadecapeptide which c... | 02/06/1990 |
| 4886663 | Synthetic heat-stable enterotoxin polypeptide of Escherichia coli and multimers thereof A synthetic polypeptide having at least about 10% of the immunological activity of biologic heat-stable enterotoxin of E. coli. The synthetic polypeptide includes at least 14 amino acids in the sequence, from amino-terminus to carboxy-terminus, represente... | 12/12/1989 |
| 4762713 | Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers This invention relates to immunogenic conjugates of capsular polymers or polymer fragments from bacterial pathogens and bacterial toxins, toxoids or subunits. The invention also relates to methods for the preparation of the conjugates and a vaccine contai... | 08/09/1988 |
| 4761283 | Immunogenic conjugates An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having a reducing end and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The invention also ... | 08/02/1988 |
| 4751064 | Synthetic chollera vaccine A synthetic vaccine against cholera and against heat-labile toxin of E. coli comprising a conjugate of a high-molecular weight carrier with a synthetic polypeptide corresponding to part of the sequence of Subunit B of natural cholera toxin. The sequences ... | 06/14/1988 |
